Under the collaboration, Evotec will receive access to longitudinal samples from an international patient cohort, collected under a MRC funded global challenges project, which includes several hundreds of patients from Asia, India and Africa linked to anonymised clinical records.
Currently, diagnosis of nephrotic syndrome, which is a group of symptoms like proteinuria and edema that indicate kidneys are not working properly, remains challenging and current treatment regimens are mostly symptomatic.
Evotec will analyse the samples using its proprietary multi-omics platform EVOpanOmics. Expert teams at Evotec and Bristol will leverage Evotec’s data analytics and prediction platform EVOpanHunter to jointly identify key drivers of nephrotic syndrome disease progression and potential molecular targets for intervention as well as molecular markers for diagnosis.